By univariate survival analysis, Bcl-2 positivity was associated with a favorable outcome in the global cohort, in terms of disease-free interval (HR = 0.44, 95% CI: 0.27–0.71; p = 0.007; Fig.2a), overall survival (HR = 0.61, 95%-CI: 0.43–0.88; p = 0.019; Fig. 2b), and cancer-specific survival (HR = 0.59, 95% CI: 0.39–0.90; p = 0.030; Fig. 2c). The gene discussed is BCL2; the disease is cancer.